Evotec SE (NASDAQ:EVO – Free Report) – Equities researchers at HC Wainwright issued their FY2024 earnings estimates for Evotec in a report issued on Thursday, April 25th. HC Wainwright analyst D. Tsao forecasts that the company will post earnings per share of ($0.10) for the year. HC Wainwright currently has a “Buy” rating and a $11.00 price target on the stock. The consensus estimate for Evotec’s current full-year earnings is ($0.23) per share. HC Wainwright also issued estimates for Evotec’s FY2025 earnings at $0.02 EPS, FY2026 earnings at $0.36 EPS and FY2027 earnings at $0.42 EPS.
A number of other equities research analysts also recently weighed in on EVO. Royal Bank of Canada raised shares of Evotec from a “sector perform” rating to an “outperform” rating in a report on Thursday, January 18th. Deutsche Bank Aktiengesellschaft raised Evotec from a “hold” rating to a “buy” rating in a report on Friday, April 12th.
Evotec Price Performance
EVO opened at $5.19 on Monday. The stock’s fifty day moving average is $7.16 and its 200-day moving average is $8.55. Evotec has a one year low of $4.87 and a one year high of $13.49.
Institutional Trading of Evotec
Hedge funds have recently modified their holdings of the business. Mubadala Investment Co PJSC acquired a new stake in shares of Evotec during the 4th quarter valued at $53,931,000. Optiver Holding B.V. grew its stake in Evotec by 643.1% in the fourth quarter. Optiver Holding B.V. now owns 80,810 shares of the company’s stock valued at $945,000 after purchasing an additional 69,936 shares in the last quarter. Finally, Quadrant Capital Group LLC acquired a new position in Evotec in the 4th quarter worth about $25,000. Hedge funds and other institutional investors own 5.81% of the company’s stock.
About Evotec
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health.
Featured Stories
- Five stocks we like better than Evotec
- How to Calculate Retirement Income: MarketBeat’s Calculator
- NXP Semiconductors Will Set a New High Soon: $300 in Sight
- Consumer Discretionary Stocks Explained
- Hilton Demonstrates Asset Light is Right for Investors
- Why Invest in High-Yield Dividend Stocks?
- Boston Scientific Bucks the Medtech Slow Down and Raises Outlook
Receive News & Ratings for Evotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec and related companies with MarketBeat.com's FREE daily email newsletter.
